NTRK1 and breast cancer: In breast cancer patients, increased TrkA phosphorylation has been described in malignant pleural effusions [24] while phosphorylation of Tyr674/675 and activation of tyrosine kinase activity in the cytoplasmic domain of TrkA has been shown as a potential prognostic biomarker [25].